A nonsteroidal anti-inflammatory drug, Diclofenac sodium is used to treat inflammation and as a pain killer. It inhibits prostaglandin synthesis by inhibition of cyclooxygenase (COX).Reference standards of Diclofenac API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => diclofenac sodium (619RB) [catalogue_number] => PA BP619RB [category_ids] => ,153, [chemical_name] => [weight] => NA [form] => NA [cas] => NA [pslug] => diclofenac-sodium-619rb-pabp619rb [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA BP619RB
CAS :
Molecular Formula : NA
Molecular Weight : NA
stdClass Object ( [pname] => diclofenac diethylamine (598RB) [catalogue_number] => PA BP598RB [category_ids] => ,153, [chemical_name] => [weight] => NA [form] => NA [cas] => NA [pslug] => diclofenac-diethylamine-598rb-pabp598rb [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA BP598RB
stdClass Object ( [pname] => diclofenac impurity A (828RB) [catalogue_number] => PA BP828RB [category_ids] => ,153, [chemical_name] => [weight] => NA [form] => NA [cas] => NA [pslug] => diclofenac-impurity-a-828rb-pabp828rb [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA BP828RB
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
